1-anilino-8-naphthalenesulfonate has been researched along with Nephrotic Syndrome in 18 studies
1-anilino-8-naphthalenesulfonate: RN given refers to parent cpd
8-anilinonaphthalene-1-sulfonic acid : A naphthalenesulfonic acid that is naphthalene-1-sulfonic acid substituted by a phenylamino group at position 8.
Nephrotic Syndrome: A condition characterized by severe PROTEINURIA, greater than 3.5 g/day in an average adult. The substantial loss of protein in the urine results in complications such as HYPOPROTEINEMIA; generalized EDEMA; HYPERTENSION; and HYPERLIPIDEMIAS. Diseases associated with nephrotic syndrome generally cause chronic kidney dysfunction.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Triamcinolone treatment did not affect plasma protein and albumin levels but increased the level of plasma triglycerides and cholesterol in the very low density lipoprotein (VLDL) and LDL but not high density lipoprotein fractions." | 5.29 | Hyperlipoproteinemia of aminonucleoside-induced nephrotic syndrome--modulation by glucocorticoids and triiodothyronine. ( Shafrir, E, 1996) |
| "Nephrotic syndrome is a highly prevalent disease that is associated with high morbidity despite notable advances in its treatment." | 2.58 | Dyslipidaemia in nephrotic syndrome: mechanisms and treatment. ( Agrawal, S; Fornoni, A; Smoyer, WE; Zaritsky, JJ, 2018) |
| "Triamcinolone treatment did not affect plasma protein and albumin levels but increased the level of plasma triglycerides and cholesterol in the very low density lipoprotein (VLDL) and LDL but not high density lipoprotein fractions." | 1.29 | Hyperlipoproteinemia of aminonucleoside-induced nephrotic syndrome--modulation by glucocorticoids and triiodothyronine. ( Shafrir, E, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 10 (55.56) | 18.7374 |
| 1990's | 5 (27.78) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (16.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Agrawal, S | 1 |
| Zaritsky, JJ | 1 |
| Fornoni, A | 1 |
| Smoyer, WE | 1 |
| Vaziri, ND | 2 |
| Zhu, Y | 1 |
| Dong, J | 1 |
| Wang, P | 1 |
| Huang, H | 1 |
| Jin, X | 1 |
| Zhou, J | 1 |
| Shi, J | 1 |
| Gu, G | 1 |
| Chen, J | 1 |
| Xu, J | 1 |
| Song, Y | 1 |
| CAREDDU, P | 1 |
| CABASSA, N | 1 |
| RAO, R | 1 |
| CHITRA, DR | 1 |
| LAKSHMINARAYANA, G | 1 |
| LARCAN, A | 1 |
| WOLFF, J | 1 |
| WOLFF, R | 1 |
| Riesen, WF | 1 |
| Mordasini, R | 1 |
| Chan, MK | 1 |
| Persaud, JW | 1 |
| Varghese, Z | 1 |
| Moorhead, JF | 1 |
| Breier, C | 1 |
| Lisch, HJ | 1 |
| Drexel, H | 1 |
| Braunsteiner, H | 1 |
| Yamada, N | 1 |
| Murase, T | 1 |
| Akanuma, Y | 1 |
| Itakura, H | 1 |
| Kosaka, K | 1 |
| Packard, CJ | 2 |
| Shepherd, J | 2 |
| Shafrir, E | 1 |
| Liang, K | 1 |
| Samsonov, MA | 1 |
| Poliantseva, LR | 1 |
| Kulikov, IuF | 1 |
| Frolova, IA | 1 |
| Tsagikian, TA | 1 |
| Beaumont, JL | 1 |
| Antonucci, M | 1 |
| Berard, M | 1 |
| Massy, ZA | 1 |
| Lacour, B | 1 |
| Warwick, GL | 1 |
| Stewart, JP | 1 |
| Watson, TD | 1 |
| Burns, L | 1 |
| Boulton-Jones, JM | 1 |
| Nikiforova, NV | 1 |
| Shallaeva, VV | 1 |
| Malakhova, EA | 1 |
| Zolotova, TA | 1 |
| Miroshnichenko, NG | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Estudio clínico Fase III Para Evaluar la Eficacia terapéutica en Pacientes Mexicanos Con Dislipidemia Mediante el Uso vía Oral de L-Carnitina + Atorvastatina Comparado Con Atorvastatina[NCT03696940] | Phase 3 | 120 participants (Actual) | Interventional | 2018-05-28 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 reviews available for 1-anilino-8-naphthalenesulfonate and Nephrotic Syndrome
| Article | Year |
|---|---|
Dyslipidaemia in nephrotic syndrome: mechanisms and treatment.
Topics: Anticholesteremic Agents; Cholesterol; Cholesterol, HDL; Cholesterol, VLDL; Dyslipidemias; Ezetimibe | 2018 |
Disorders of lipid metabolism in nephrotic syndrome: mechanisms and consequences.
Topics: Cholesterol; Creatinine; Dyslipidemias; Humans; Lipase; Lipoproteins; Liver; Nephrotic Syndrome; Pro | 2016 |
Lipoprotein metabolism in lipase deficient states: studies in primary and secondary hyperlipidaemia.
Topics: Humans; Hyperlipidemias; Hypothyroidism; Lipase; Lipoprotein Lipase; Lipoproteins; Liver; Nephrotic | 1993 |
[Apolipoprotein C-III in nephrology].
Topics: Apolipoprotein C-III; Apolipoproteins C; Female; Humans; Kidney Failure, Chronic; Lipase; Lipoprotei | 1992 |
14 other studies available for 1-anilino-8-naphthalenesulfonate and Nephrotic Syndrome
| Article | Year |
|---|---|
Serum Lipase as Clinical Laboratory Index for Chronic Renal Failure Diagnosis.
Topics: Adult; Aged; Aged, 80 and over; Amylases; Biomarkers; Case-Control Studies; Clinical Enzyme Tests; C | 2016 |
[Lipoprotein lipase activity in the nephrotic syndrome].
Topics: Humans; Lipase; Lipoprotein Lipase; Nephrotic Syndrome | 1958 |
SERUM TRIBUTYRINASE LEVELS IN HEALTH AND DISEASE.
Topics: Anemia; Anemia, Macrocytic; Clinical Enzyme Tests; Diabetes Mellitus; Dyspepsia; Female; Glomerulone | 1963 |
[The clearing factor and the inhibiting factor during lipoid nephrosis].
Topics: Humans; Lipase; Lipids; Lipoprotein Lipase; Lipoproteins; Nephrosis, Lipoid; Nephrotic Syndrome | 1961 |
Hyperlipidemia in renal failure: phenotypes and pathogenetic mechanisms.
Topics: Humans; Hyperlipoproteinemias; Kidney Failure, Chronic; Kidney Transplantation; Lipase; Lipoprotein | 1984 |
Post-heparin hepatic and lipoprotein lipase activities in nephrotic syndrome.
Topics: Adolescent; Adult; Child; Cholesterol, HDL; Female; Humans; Hypercholesterolemia; Lipase; Lipoprotei | 1984 |
[Lipoproteins, apolipoproteins, lipoprotein lipase, hepatic triglyceride lipase and lecithin cholesterol acyltransferase in patients with nephrotic syndrome].
Topics: Adolescent; Adult; Apolipoproteins; Arteriosclerosis; Creatinine; Female; Humans; Hyperlipoproteinem | 1983 |
Ascites chylomicron: a poor substrate for hepatic triglyceride lipase.
Topics: Ascites; Cholesterol; Chylomicrons; Humans; Kinetics; Lipase; Lipoprotein Lipase; Lipoproteins, VLDL | 1981 |
Hyperlipoproteinemia of aminonucleoside-induced nephrotic syndrome--modulation by glucocorticoids and triiodothyronine.
Topics: Animals; Blood Proteins; Fatty Acids, Nonesterified; Glucocorticoids; Gluconeogenesis; Hyperlipoprot | 1996 |
Down-regulation of hepatic lipase expression in experimental nephrotic syndrome.
Topics: Animals; Cholesterol; Lipase; Liver; Male; Nephrotic Syndrome; Proteinuria; Rats; Rats, Sprague-Dawl | 1997 |
[Change of the enzyme-secretory function of the pancreas in nephrotic syndrome].
Topics: Adolescent; Adult; Amylases; Female; Humans; Lipase; Male; Middle Aged; Nephrotic Syndrome; Pancreas | 1978 |
Autoimmune hyperlipidemia in the nephrotic syndrome.
Topics: Antigen-Antibody Reactions; Autoimmune Diseases; Humans; Hyperlipidemias; Lipase; Lipoprotein Lipase | 1977 |
Post-prandial lipoprotein metabolism in nephrotic syndrome.
Topics: Adult; Aged; Chylomicrons; Dietary Fats; Diterpenes; Female; Humans; Hyperlipidemias; Lipase; Lipopr | 1992 |
[Lipolytic enzyme activity in the plasma of patients with nephrotic syndrome].
Topics: Adolescent; Adult; Female; Humans; Lipase; Lipoprotein Lipase; Male; Nephrotic Syndrome | 1985 |